Rituximab Treatment Outcomes for Anti-GBM Disease in a 66-Patient Cohort

A retrospective cohort analysis of 66 patients with anti-glomerular basement membrane disease, comparing conventional therapy with and without rituximab. The dataset, authored by Yulin Wang and last updated in 2026, includes baseline characteristics, treatment responses, and long-term renal outcomes. It likely contains clinical and pathological variables used to assess factors associated with end-stage renal disease.

Use Cases

• Compare time to dialysis independence between treatment groups based on the reported median days.
• Analyze factors associated with progression to end-stage renal disease based on prognostic variables like baseline renal function and anemia.
• Model renal survival probabilities using the Kaplan-Meier hazard ratio data mentioned in the results.
• Evaluate the balance of baseline clinical and pathological characteristics between patient cohorts.

Strengths

• Includes data from 66 patients, with 14 in the rituximab group and 52 in the control group.
• Reports specific clinical outcomes, including median time to dialysis independence (26 vs. 41 days) and 3-year ESRD incidence rates.
• License is CC-BY-4.0, allowing for open sharing and adaptation.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small at 19.5 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Retrospective cohort analysis of patient records.

Freshness

Last updated 2026-05-11 05:25:09; freshness should be verified.